Abstrait
Le cancer du sein représente un problème majeur de santé publique. Depuis 1960, il constitue la première cause de décès par cancer chez la femme et son incidence ne cesse ďaugmenter. Actuellement, ce cancer touche une femme sur 10 et une femme sur 25 en meurt. En 2003, aux États-Unis, environ 211000 nouveaux cas et 40000 décès ont été déclarés. En France, ľétude de Hill et Doyon (3) rapporte 42000 nouveaux cas et 11000 décès pour ľannée 2000.
Preview
Unable to display preview. Download preview PDF.
Références
S, Bougnoux P, Penault-Llorca F, et al. (2003) Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. British Journal of Cancer 88: 1339–45
Barni S, Visini M, Piazza E et al. (2002) Cisplatin-Epirubicin-Vinorelbine (PEV): a new neoadjuvant chemotherapy for stage T2-3/N0-2 breast cancer patients pts). Proc Annu Meet Am Soc Clin Oncol, 21: abstract 1961, p 37b
Bear HD, Anderson S, Brown A et al. (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast an Bowel Project Protocol B-27. J Clin Oncol, 21: 4165–74
Belembaogo E, Feillel V, Chollet P et al. (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. European Journal of Cancer 28: 896–900
Bonadonna G, Valagussa P, Brambilla C et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100
Chevallier B, Roche H, Olivier J.P et al. (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. American Journal of Clinical Oncology 16: 223–8
Chevallier B., Chollet P., Merrouche Y. et al. (1995) Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13: 1564–71
Chollet P, Charrier S, Brain E et al. (1997) Clinical and pathological response to primary chemotherapy in inoperable breast cancer. European Journal of Cancer 33: 862–6
Curé H, Charrier S, Ferrière JP et al. (1997) Chimiothérapie première dans les cancers du sein opérables supérieurs à 3 cm: résultats de 3 protocoles. Bulletin du Cancer 84: 31–4
De Lena M, Varini M, Zucali R et al. (1981) Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229–36
Diéras V, Fumoleau P, Romieu G et al. (1998) A randomized parallel study of doxorubicin/taxol (AT) and doxorubicine/cyclophosphamide (AC) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 50: 233 (abst 25)
Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings form National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–93
Fumoleau P, Tubiana-Hulin M, Romieu G et al. (2001) A randomized phase II study of 4 or 6 cycles of adriamycin/taxol® (paclitaxel) as neoadjuvant treatment of breast cancer. Annals of Oncology, abst. 508.
Heys SD, Hutcheon AW, Sarkar TK et al. (2002) Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clinical Breast Cancer 3 Suppl 2: S69–74
Hortobagyi GN, Ames FC, Buzdar AU et al. (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–16
Jacquillat C, Weil M, Baillet F et al. (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast conservating treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119–29
Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10: 1014–24
Luporsi E, Vanlemmens L, Coudert B et al. (2000) 6 cycles of FEC 100 vs 6 cycles of Epirubicin Docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized phase II of GIREC S01. Proc Am Soc Clin Oncol 19: 92 a (abstr 355)
Mauriac L, Durand M, Avril A et al. (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347–54
Mouret-Reynier MA, Abrial C, Ferrière JP et al. (2004) Neoadjuvant FEC 100 for operable breast cancer: Eight-year experience at Centre Jean-Perrin. Clinical Breast Cancer, (accepted)
Ogston KN, Miller ID, Payne S et al. (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast, 12: 320–7
Powles TJ, Hickish TF, Makris A et al. (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–52
Sataloff DM, Mason BA, Prestipino AJ et al. (1995) J Am Coll Surg, 180: 297–306
Scholl SM, Fourquet A, Asselain B et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenaupausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645–52
Smith IE, Jones AL, O’Brien ME et al. (1993) Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 592–5
Smith GA, Henderson IC (1995) High dose chemotherapy (HDC) with Autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important advances in oncology 1995, edited by Vincent T De Vita, Samuel Hellman, and Steven A. Rosenberg. J.B. Lippincott company, Philadelphia
Smith IE, A’Hern R, Coombes G et al. (2003) A randomised neoadjuvant chemotherapy trial of Vinorelbine/Epirubicin (VE) vs standard Doxorubicin/Cyclophosphamide (DC) in patients with >=3 cm diameter operable breast cancer (topic 2). Proc Annu Meet Am Soc Clin Oncol, 22: 21-Abst.83
Van Praagh I, Curé H, Leduc B et al. (2002) Efficacy of primary chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist, 7:418–23
Van Praagh I, Amat S, Leduc B et al. (2002) Induction chemotherapy in operable breast cancer by NET regimen: multicentric phase II trial. Annals of Oncology, 13: 43-abst.153
Viens P, Palangié T, Janvier M et al. (1999) Fist line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (Pegase 02 program). British Journal of Cancer 81: 449–56
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag France
About this chapter
Cite this chapter
Abrial, C., Penault-Llorca, F., Mouret-Reynier, M.A., Curé, H., Chollet, P. (2007). Quand faire de la chimiothérapie néoadjuvante? Ľutilisation de la chimiothérapie néoadjuvante chez des patientes atteintes de cancer du sein opérable (stades II et III). In: Le cancer du sein. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36073-2_7
Download citation
DOI: https://doi.org/10.1007/978-2-287-36073-2_7
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-36071-8
Online ISBN: 978-2-287-36073-2